Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Satellos Bioscience Inc. (TSX: MSCL) (OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle...
- Completed enrollment for SAT-3247 in Duchenne muscular dystrophy (DMD) in the first three (of five) single-ascending dose (SAD) cohorts with no safety concerns and initiated enrollment of first...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle...
- Analysis showed improvement in muscle morphology and increased levels of regeneration in muscle groups, including the diaphragm, quadriceps, and calf - No adverse events and no significant...
- The first healthy volunteer has been dosed in the first component of the Phase 1 study - Initial safety and pharmacokinetic data expected in Q4 2024 - Initiation of the second component of...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle...
Dosing of first participant in a Phase 1 clinical trial of SAT-3247 anticipated in Q3 2024 Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech...
- Updated data in a canine model of Duchenne muscular dystrophy (DMD) show further increased improvement in muscle force over baseline of 195% at four-month point - Receipt of Orphan Drug and...
– SAT-3247 is a proprietary, oral small molecule drug being developed by Satellos as a novel treatment to regenerate skeletal muscle which is lost in Duchenne muscular dystrophy (DMD) – DMD is a...
– Investigational New Drug (IND) enabling preclinical and toxicology studies successfully completed – Initiation of a Phase 1 clinical trial of SAT-3247 anticipated in Q3 2024 Satellos Bioscience...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.09 | -10.9756097561 | 0.82 | 0.82 | 0.67 | 158631 | 0.77031909 | CS |
| 4 | -0.11 | -13.0952380952 | 0.84 | 0.9 | 0.67 | 118649 | 0.8195762 | CS |
| 12 | 0.19 | 35.1851851852 | 0.54 | 0.9 | 0.45 | 134066 | 0.69001167 | CS |
| 26 | 0.22 | 43.137254902 | 0.51 | 0.9 | 0.45 | 94076 | 0.63332601 | CS |
| 52 | 0.11 | 17.7419354839 | 0.62 | 0.9 | 0.38 | 83545 | 0.61095631 | CS |
| 156 | 0.11 | 17.7419354839 | 0.62 | 0.9 | 0.38 | 83545 | 0.61095631 | CS |
| 260 | 0.11 | 17.7419354839 | 0.62 | 0.9 | 0.38 | 83545 | 0.61095631 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
